Innate Pharma Receives Strong Buy Recommendation for Cancer Drug Potential
Innate Pharma got a "Buy" rating & $8 target. Its cancer drug IPH4502 targets a huge $1.5 billion bladder cancer market.
NOTRELOAD AI
Super Micro Q1 Revenue Miss: AI Server Orders Delayed
Super Micro missed its quarterly revenue goal due to delayed customer orders for AI systems, but the CEO insists demand is soaring.
Globalstar Eyes $10B+ Sale as Apple-SpaceX Satellite Battle Heats Up
Globalstar chairman James Monroe discusses potential $10B+ sale while SpaceX positions itself to compete with Apple's satellite iPhone features.
Viking Therapeutics Stock Soars: Major Price Target Increases from Wall Street
Morgan Stanley, Cantor Fitzgerald, and BTIG raise Viking Therapeutics (VKTX) price targets to $102-$125, citing accelerated obesity trials and upcoming FDA meeting for oral treatment.
Dow Chemicals Beats Q3 Loss Expectations on Cost Cuts and New Assets
Dow Chemical reports smaller Q3 loss than expected, driven by cost reductions and new Gulf Coast facilities.
Freeport-McMoRan Beats Q3 Profit Expectations Despite Indonesia Mine Incident
Freeport-McMoRan exceeds Q3 profit forecasts with 50 cents per share as higher copper prices offset production losses from Grasberg mine suspension following tragic mud rush incident.